| Literature DB >> 23611284 |
Panagiotis Ntziachristos1, Jasper Mullenders, Thomas Trimarchi, Iannis Aifantis.
Abstract
Over the past decade, it has become clear that both genetics and epigenetics play pivotal roles in cancer onset and progression. The importance of epigenetic regulation in proper maintenance of cellular state is highlighted by the frequent mutation of chromatin modulating factors across cancer subtypes. Identification of these mutations has created an interest in designing drugs that target enzymes involved in DNA methylation and posttranslational modification of histones. In this review, we discuss recurrent genetic alterations to epigenetic modulators in both myeloid and lymphoid leukemias. Furthermore, we review how these perturbations contribute to leukemogenesis and impact disease outcome and treatment efficacy. Finally, we discuss how the recent advances in our understanding of chromatin biology may impact treatment of leukemia.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23611284 PMCID: PMC3830954 DOI: 10.1016/B978-0-12-410524-9.00001-3
Source DB: PubMed Journal: Adv Immunol ISSN: 0065-2776 Impact factor: 3.543